Eric Ostertag, M.D., Ph.D.

ostertag@transposagenbio.com

Better Models. Better ResultsTM

SBIR/STTR Success Stories – Lessons Learned

PhenoTech Inc. ◦ Diagnostics ◦ (1) Phase 1 and (1) Phase 2 grants (>$1M)

Transposagen Biopharmaceuticals Inc. ◦ Research tools ◦ (6) Phase 1 and (2) Phase 2 grants (~$5M)

Vindico NanoBioTechnology Inc. ◦ Therapeutics ◦ (3) Phase 1 grants (>$1M)

1988 - Nature – Kazazian discovers

active LINE1 retrotransposons in

humans

2002 - Nature Genetics – Ostertag

creates first mouse model of

retrotransposition

2003 - Transposagen incorporated

2005 - Company gets Phase I SBIR

2007 - Company gets Phase II SBIR

•2008 - Launch of first products - Phase II SBIR Match

•2009 - Moved Company to Lexington, KY

•2010 - Company becomes cash positive

•2011 - Series A investment

2012 - Expansion of facilities and staff

Transposagen’s History

NHLBI

NCRR (OD)

NCI

NHGRI

NIGMS

NIAID

Advantages ◦ Non-dilutive funding ◦ Peer review of proposal ◦ Viewed positively by investors

Disadvantages ◦ Restricted funds ◦ Reimbursement-basis ◦ A lot of work to get ◦ Not all grants get funded ◦ Special accounting ◦ Need to request budget changes and extensions ◦ Interacting with funding agency

State-specific matching programs ◦ Phase 0

◦ Matching Phase I and Phase II (KY only)

Research Opportunities ◦ Cover letter

Target specific ICs – get dual assignment

Target specific study sections

Contact targeted ICs